11 C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI
- 25 January 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (2) , 332
- https://doi.org/10.1212/wnl.54.2.332
Abstract
Background: Using 11C-flumazenil (FMZ) PET with correction for partial-volume effect, reductions of central benzodiazepine receptor (cBZR) binding can be detected reliably in vivo on remaining neurons in sclerotic hippocampi of patients with mesial temporal lobe epilepsy (TLE). Objective: To delineate abnormalities of 11C-FMZ binding in patients with medically refractory TLE and normal quantitative MRI. Methods: Analysis of parametric images of FMZ volume of distribution (Vd) using two complementary approaches: 1) MRI-based volume of interest (VOI) approach with partial volume effect correction for multiple hippocampal and extrahippocampal VOIs; and 2) statistical parametric mapping (SPM) to localize significant 11C-FMZ binding changes objectively on a voxel-by-voxel basis. Results: Significant abnormalities of absolute FMZ-Vd were found after partial volume effect correction in 5 of 10 patients: unilateral decrease in the amygdala ipsilateral to the EEG focus (1), unilateral hippocampal decreases and bilateral temporal and extratemporal neocortical decreases (2), unilateral increase in the temporal neocortex together with extratemporal neocortical increases (1), and bilateral posterior hippocampal increases together with temporal neocortical increases (1). In the three patients with extratemporal neocortical changes, the concomitant unilateral hippocampal or temporal neocortical changes were contralateral to the presumed epileptic focus. Significant asymmetries of FMZ-Vd between homologous regions were found in six patients. In four of those patients, absolute FMZ-Vd for the homologous regions were within normal limits, with two of the four patients showing relatively higher hippocampal values ipsilateral to the presumed epileptic focus. SPM analysis localized significant abnormalities of FMZ-Vd in similar locations in three of the seven patients in whom VOI analysis detected significant changes. In addition, SPM indicated significant unilateral contralateral hippocampal decreases in an eighth patient. However, both methods failed to localize epileptic foci in two patients identified by depth-EEG recordings. Conclusions:11C-FMZ PET showed focal increases as well as decreases of FMZ binding in 80% of patients with refractory TLE and normal high-quality MRI but was not consistently helpful in localizing the epileptic foci.Keywords
This publication has 26 references indexed in Scilit:
- In vivo [11C] flumazenil‐PET correlates with ex vivo [3H] flumazenil autoradiography in hippocampal sclerosisAnnals of Neurology, 1998
- Extratemporal atrophy in patients with complex partial seizures of left temporal originAnnals of Neurology, 1998
- Cortical grey matter and benzodiazepine receptors in malformations of cortical development. A voxel-based comparison of structural and functional imaging dataBrain, 1997
- Regional hippocampal [11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosisBrain, 1997
- Central benzodiazepine receptor autoradiography in hippocampal sclerosisBritish Journal of Pharmacology, 1997
- The spectrum of hippocampal sclerosis: A quantitative magnetic resonance imaging studyAnnals of Neurology, 1997
- Cerebral benzodiazepine receptors in hippocampal sclerosisBrain, 1996
- MRI-Guided Flumazenil- and FDG-PET in Temporal Lobe EpilepsyNeuroImage, 1996
- Parametric in vivo imaging of benzodiazepine receptor distribution in human brainAnnals of Neurology, 1991
- Synthesis of ethyl 8-fluoro-5,6-dihydro5- [11C]methyl-6-oxo-4H-imidazo[1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): A specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomographyThe International Journal of Applied Radiation and Isotopes, 1984